A Phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refract

The research is designed to test rapcabtagene autoleucel (administered once following lymphodepletion) versus Standard of Care (SOC) in patients with systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN). The primary purpose of this study is to evaluate the safety and efficacy of rapcabtagene autoleucel by measuring the Percentage of participants achieving remission after 1 year.

Sponsor

Novartis Pharmaceuticals 

Status of enrollment

Accepting new patients

Ages Eligible for Study

Adults aged 18-65 years

Genders Eligible for Study

Female and Male

Disease indication

Systemic Lupus Erythematosus (SLE) with Lupus Nephritis (LN)

Principal Investigator

Emily Von Scheven MD

Contact

Zilan Zheng 

zilan.zheng@ucsf.edu

 

 

Additional study eligibility details can be found at UCSF Clinical Trials.